Comprehensive analysis of "bath salts" purchased from California stores and the internet

Clinical Toxicology

Volumn 52, Issue 7, 2014, Pages 651-658

  Schneir, A ^a   Ly, B T ^a   Casagrande, K ^b   Darracq, M ^a   Offerman, S R ^c   Thornton, S ^a   Smollin, C ^d   Vohra, R ^d   Rangun, C ^e   Tomaszewski, C ^a   Gerona, R R ^d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c KAISER PERMANENTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Los Angeles County Department of Public Health   (United States)

Author keywords

"bath salts"; Cathinones; Quantification; TOF

Indexed keywords

" BATH SALTS"; CATHINONES; QUANTIFICATION; TOF;

ALKALOIDS; BENZODIOXOLES; CALIFORNIA; CENTRAL NERVOUS SYSTEM STIMULANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DESIGNER DRUGS; DRUG COMBINATIONS; DRUG LABELING; INTERNET; MOLECULAR STRUCTURE; PSYCHOTROPIC DRUGS; PYRROLIDINES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STREET DRUGS;

EID: 84905508990     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2014.933231     Document Type: Article

References (37)

1. Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical conspecificrmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin Toxicol (Phila) 2011 ; 49 : 499-505.
2. Centers for Disease Control and Prevention (CDC). Emergency department visits after use of a drug sold as "bath salts "-Michigan, November 13, 2010-March 31, 2011. MMWR Morb Mortal Wkly Rep 2011; 60 : 624-627.
3. Warrick BJ, Hill M, Hekman K, Christensen R, Goetz R, Casavant MJ, et al. A 9-state analysis of designer stimulant, "Bath Salt, " hospital visits reported to poison control centers. Ann Emerg Med 2013 Mar 20.
4. Murray B L, Murphy C M, Beuhler M C. Death following recreational use of designer drug "bath salts " containing 3,4-methylenedioxypyrovalerone (MDPV). J Med Toxicol 2012 ; 8 : 69-75.
5. Borek H A, Holstege C P. Hyperthermia and multiorgan failure after abuse of "bath salts " containing 3,4-methylenedioxypyrovalerone. Ann Emerg Med 2012 ; 60 : 103-105.
6. Murphy C M, Dulaney A R, Beuhler M C, Kacinko S. "Bath salts" and "plant food " products: the experience of one regional US poison control center. J Med Toxicol 2013 ; 9 : 42-48.
7. Davies S, Wood DM, Smith G, Button J, Ramsey J, Archer R, et al. Purchasing legal highs on the Internet-is there consistency in what you get? QJM 2010 ; 103 : 489-493.
8. Davies S, Lee T, Ramsey J, Dargan P I, Wood D M. Risk of caffeine toxicity associated with the use of legal highs (novel psychoactive substances). Eur J Clin Pharmacol 2012 ; 68 : 435-439.
9. Ramsey J, Dargan P I, Smyllie M, Davies S, Button J, Holt D W, Wood DM. Buying legal recreational drugs does not mean that you are not breaking the law. QJM 2010 ; 103 : 777-783.
10. Brandt SD, Sumnall HR, Measham F, Cole J. Analyses of secondgeneration legal highs in the UK: initial findings. Drug Test Anal. 2010 ; 2 : 377-382.
11. Brandt SD, Freeman S, Sumnall HR, Measham F, Cole J. Analysis of NRG legal highs in the UK: Identification and formation of novel cathinones. Drug Test Anal 2011 ; 3 : 569-575.
12. B aron M, E lie M, E lie L. A n analysis of legal highs: do they contain what it says on the tin? Drug Test Anal 2011 ; 3 : 576-581.
13. Ayres TC, Bond JW. A chemical analysis examining the pharmacology of novel psychoactive substances freely available over the internet and their impact on public (ill)health. Legal highs or illegal highs? BMJ Open 2012 ; 2.
14. Reitzel L A, Dalsgaard P W, Muller I B, Cornett C. Identispecificcation of ten new designer drugs by GC-MS, UPLC-QTOF-MS, and NMR as part of a police investigation of a Danish internet company. Drug Test Anal 2012 ; 4 : 342-354
15. Corkery JM, Elliot S, Schifano F, Corazza OR, Ghodse AH. 2-DPMP (desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol): a preliminary review. Prog Neuropsychopharmacol Biol Psychiatry 2012 ; 39 : 253-258.
16. Shanks KG, Dahn T, Behonick G, Terrell A. Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry. J Anal Toxicol 2012 ; 36 : 360-371.
17. Drug Enforcement Administration. Schedules of controlled substances: temporary placement of three synthetic cathinones into schedule I. Fed Regist 2011 ; 76 : 65371-65375.
18. Thornton SL, Gerona RR, Tomaszewski CA. Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification. J Med Toxicol 2012 ; 8 : 310-313.
19. Marinetti LJ, Antonides HM. Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. J Analy Toxicol 2013 ; 37 : 135-146.
20. Gerona RR, Wu AH. Bath salts. Clin Lab Med. 2012 ; 32 : 415-427.
21. Wu AH, Gerona R, Armenian P, French D, Petrie M, Lynch KL. Role of liquid chromatography-high-resolution mass spectrometry (LC-HR/MS) in clinical toxicology. Clin Toxicol (Phila) 2012 ; 50 : 733-742.
22. Polettini A, Gottardo R, Pascali JP, Tagliaro F. Implementation and performance evaluation of a database of chemical formulas for the screening of pharmaco/toxicologically relevant compounds in biological samples using electrospray ionization-time-of-flight mass spectrometry . Anal Chem 2008 ; 80 : 3050-3057.
23. Guale F, Shahreza S, Walterscheid JP, Chen HH, Arndt C, Kelly AT, Mozayani A. Validation of LC-TOF-MS screening for drugs, metabolites, and collateral compounds in forensic toxicology specimens. J Anal Toxicol 2013 ; 37 : 17-24.
24. Federal Analog Act. Available at: http://www.gpo.gov/fdsys/pkg/USCODE- 2008-title21/pdf/USCODE-2008-title21-chap13-subchapIpartB-sec813.pdf (Accessed on April 10th, 2014).
25. Dickson Amber J, Vorce SP, Levine B, Past MR. Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin. J Analyt Toxicol 2010 ; 34 : 162-168.
26. Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J. In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos 1998; 26: 536-539.
27. Pederson AJ, Petersen TH, Linnet K. In vitro metabolism and pharmacokinetics studies on methylone. Drug Metab Dispos 2013; 41: 1247-1255
28. Meyer MR, Peng D, Schuster F, Maurer HH. Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy- pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. J Mass Spectrom 2010 ; 45 : 1426-1442.
29. Sauer C, Peters FT, Haas C, Meyer MR, Fritschi G, Maurer HH. New designer drug α-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom 2009 ; 44 : 952-964.
30. Pedersen AJ, Reitzel LA, Johansen SS, Linnet K. In vitro metabolism studies on mephedrone and analysis of forensic cases. Drug Test Anal 2013 ; 5 : 430-438.
31. Wood KE. Exposure to bath salts and synthetic tetrahydrocannabinol from 2009 to 2012 in the United States. J Pediatr 2013 ; 163 : 213-216.
32. Synthetic Drug Abuse Prevention Act of 2012. C ongressional Record-112th Congress (2011-2012). Available at: http://www. gpo.gov/fdsys/pkg/BILLS- 112s3190is/pdf/BILLS-112s3190is.pdf. Accessed June 19, 2014.
33. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: extension of temporary placement of methylone into schedule I of the Controlled Substances Act. Final order. Fed Regist 2012 ; 77 : 64032-64033.
34. Vogels N, Brunt TM, Rigter S, van Dijk P, Vervaeke H, Niesink RJ. Content of ecstasy in the Netherlands: 1993- 2008. Addiction. 2009 ; 104 :2057-2066.
35. Teng S F, Wu S C, Liu C, Li J H, Chien C S. C.haracteristics and trends of 3,4-methylenedioxymethamphetamine (MDMA) tablets found in Taiwan from 2002 to February 2005. Forensic Sci Int 2006; 161:202-208.
36. Wood D M, Stribley V, Dargan P I, Davies S, Holt D W, Ramsey J. Variability in the 3,4-methylenedioxymethamphetamine content of ecstasy tablets in the UK. Emerg Med J 2011 ; 28 : 764-765.
37. Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 2012 ; 8 : 33-42.